ATE488501T1 - Cyclopropylpiperidinglycin-transporter-inhibito - Google Patents

Cyclopropylpiperidinglycin-transporter-inhibito

Info

Publication number
ATE488501T1
ATE488501T1 AT05801197T AT05801197T ATE488501T1 AT E488501 T1 ATE488501 T1 AT E488501T1 AT 05801197 T AT05801197 T AT 05801197T AT 05801197 T AT05801197 T AT 05801197T AT E488501 T1 ATE488501 T1 AT E488501T1
Authority
AT
Austria
Prior art keywords
cyclopropylpiperidinglycine
inhibito
transporter
glycine transporter
transporter glyt1
Prior art date
Application number
AT05801197T
Other languages
English (en)
Inventor
Craig Lindsley
David Wisnoski
Scott Wolkenberg
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE488501T1 publication Critical patent/ATE488501T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05801197T 2004-09-30 2005-09-26 Cyclopropylpiperidinglycin-transporter-inhibito ATE488501T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61494204P 2004-09-30 2004-09-30
PCT/US2005/034301 WO2006039221A2 (en) 2004-09-30 2005-09-26 Cyclopropyl piperidine glycine transporter inhibitors

Publications (1)

Publication Number Publication Date
ATE488501T1 true ATE488501T1 (de) 2010-12-15

Family

ID=36142986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05801197T ATE488501T1 (de) 2004-09-30 2005-09-26 Cyclopropylpiperidinglycin-transporter-inhibito

Country Status (16)

Country Link
US (1) US7776886B2 (de)
EP (1) EP1797035B1 (de)
JP (1) JP4646984B2 (de)
KR (1) KR20070058565A (de)
CN (1) CN101031547A (de)
AT (1) ATE488501T1 (de)
AU (1) AU2005292323B2 (de)
BR (1) BRPI0515954A (de)
CA (1) CA2581582C (de)
DE (1) DE602005024838D1 (de)
IL (1) IL182253A0 (de)
MX (1) MX2007003816A (de)
NO (1) NO20072208L (de)
RU (1) RU2387644C2 (de)
WO (1) WO2006039221A2 (de)
ZA (1) ZA200701612B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544981A1 (en) * 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperidine sulfonyl glycine transporter inhibitors
EP1729772B8 (de) * 2004-03-24 2017-04-19 Merck Sharp & Dohme Corp. Heteroaryl-piperidin-glycin-transporterhemmer
EP1745018A1 (de) * 2004-04-29 2007-01-24 Merck & Co., Inc. Inhibitoren des azetidinglycintransporters
WO2005107469A2 (en) * 2004-05-05 2005-11-17 Merck & Co., Inc. Morpholinyl piperidine glycine transporter inhibitors
AU2005317846B2 (en) * 2004-12-21 2011-12-08 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as GlyT1 inhibitors
JP5281395B2 (ja) * 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のglyt1阻害剤としてのシクロヘキサンスルホニル誘導体
CA2611376C (en) 2005-06-13 2013-09-10 Merck Sharp & Dohme Limited Therapeutic agents
WO2007053400A2 (en) 2005-10-28 2007-05-10 Merck & Co., Inc. Piperidine glycine transporter inhibitors
EP2403337A4 (de) * 2009-03-03 2012-08-15 Univ Vanderbilt Alkylsulfonyl-2,3-dihydrospiro[inden-1,4'-piperidin]-analoge als glyt1-hemmer, verfahren zu ihrer herstellung sowie ihre verwendung zur behandlung psychiatrischer erkrankungen
EP3134406A1 (de) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituierte 2,4,5,6-tetrahydropyrrolo [ 3,4-c ] pyrazol-und 4,5,6,7-tetrahydro-2 h-pyrazolo [ 4,3-c ] pyridinverbindungen als glyt1-inhibitoren
EP3215500A1 (de) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituierte azetidinylverbindungen als glyt1-inhibitoren

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
KR100879647B1 (ko) * 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
CA2403686C (en) 2000-03-23 2010-01-26 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
US7507767B2 (en) 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
AR037352A1 (es) * 2001-11-14 2004-11-03 Schering Corp Compuestos ligandos de los receptores de los cannabinoides, una composicion farmaceutica , y el uso de dichos compuestos para la manufactura de medicamentos
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
CA2544981A1 (en) * 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperidine sulfonyl glycine transporter inhibitors
EP1729772B8 (de) * 2004-03-24 2017-04-19 Merck Sharp & Dohme Corp. Heteroaryl-piperidin-glycin-transporterhemmer
EP1745018A1 (de) * 2004-04-29 2007-01-24 Merck & Co., Inc. Inhibitoren des azetidinglycintransporters
WO2005107469A2 (en) 2004-05-05 2005-11-17 Merck & Co., Inc. Morpholinyl piperidine glycine transporter inhibitors
AU2005317846B2 (en) 2004-12-21 2011-12-08 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as GlyT1 inhibitors
JP5281395B2 (ja) 2005-06-06 2013-09-04 メルク シャープ エンド ドーム リミテッド 統合失調症の治療用のglyt1阻害剤としてのシクロヘキサンスルホニル誘導体
EP1942733B1 (de) 2005-09-29 2012-03-21 Merck Sharp & Dohme Corp. Radioaktiv markierte glycintransporter-hemmer
WO2007053400A2 (en) 2005-10-28 2007-05-10 Merck & Co., Inc. Piperidine glycine transporter inhibitors

Also Published As

Publication number Publication date
EP1797035A4 (de) 2009-08-05
BRPI0515954A (pt) 2008-08-12
WO2006039221A2 (en) 2006-04-13
EP1797035A2 (de) 2007-06-20
AU2005292323B2 (en) 2011-06-09
DE602005024838D1 (en) 2010-12-30
ZA200701612B (en) 2009-05-27
JP4646984B2 (ja) 2011-03-09
KR20070058565A (ko) 2007-06-08
CA2581582C (en) 2010-07-20
US7776886B2 (en) 2010-08-17
IL182253A0 (en) 2007-09-20
EP1797035B1 (de) 2010-11-17
WO2006039221A3 (en) 2006-09-08
RU2007116165A (ru) 2008-11-10
RU2387644C2 (ru) 2010-04-27
AU2005292323A1 (en) 2006-04-13
CN101031547A (zh) 2007-09-05
JP2008514705A (ja) 2008-05-08
NO20072208L (no) 2007-04-27
CA2581582A1 (en) 2006-04-13
US20080108663A1 (en) 2008-05-08
MX2007003816A (es) 2007-04-24

Similar Documents

Publication Publication Date Title
WO2005046601A3 (en) 4-phenyl piperdine sulfonyl glycine transporter inhibitors
NO20072208L (no) Syklopropylpiperidinglysintransportorinhibitorer.
WO2005094514A3 (en) Heteroaryl piperidine glycine transporter inhibitors
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
ATE557021T1 (de) Zur behandlung von erkrankungen des zns geeignete derivate des 4-piperazin-1-yl-4-benzoäbüthiophens
EA200900098A1 (ru) Пептидные соединения для лечения расстройств, связанных с повышенной возбудимостью, и болезней, связанных с дисфункцией ионных каналов
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
DE602007008434D1 (de) Rezeptoren
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
WO2005063766A3 (en) Bicyclic heterocyclic p-38 kinase inhibitors
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
CY1106902T1 (el) Κρυσταλλικη μορφη μηλεϊνικης ασεναπινης
NO20080765L (no) Prodrug av eksitasjonsaminosyrer
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
BRPI0519424A2 (pt) composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular
ATE494890T1 (de) Alpha-aminoamid-derivate zur behandlung von suchtstörungen
EA200700909A1 (ru) Азаиндолкарбоксамиды
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
WO2007053400A3 (en) Piperidine glycine transporter inhibitors
TW200724140A (en) Hydantoin compounds
WO2005107469A3 (en) Morpholinyl piperidine glycine transporter inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties